{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T19:19:31Z","timestamp":1770837571950,"version":"3.50.1"},"reference-count":125,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T00:00:00Z","timestamp":1631836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Myasthenia gravis (MG) is an autoimmune disease characterized by muscle weakness and abnormal fatigability due to the antibodies against postsynaptic receptors. Despite the individual discrepancy, patients with MG share common muscle weakness, autoimmune dysfunction, and immunosuppressive treatment, which predispose them to infections that can trigger or exacerbate MG. Vaccination, as a mainstay of prophylaxis, is a major management strategy. However, the past years have seen growth in vaccine hesitancy, owing to safety and efficacy concerns. Ironically, vaccines, serving as an essential and effective means of defense, may induce similar immune cross-reactivity to what they are meant to prevent. Herein, we outline the progress in vaccination, review the current status, and postulate the clinical association among MG, vaccination, and immunosuppression. We also address safety and efficacy concerns of vaccination in MG, in relation to COVID-19. Since only a handful of studies have reported vaccination in individuals with MG, we further review the current clinical studies and guidelines in rheumatic diseases. Overall, our reviews offer a reference to guide future vaccine clinical decision-making and improve the management of MG patients.<\/jats:p>","DOI":"10.3389\/fimmu.2021.733418","type":"journal-article","created":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T06:08:54Z","timestamp":1631858934000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":26,"title":["To Be or Not To Be Vaccinated: That Is a Question in Myasthenia Gravis"],"prefix":"10.3389","volume":"12","author":[{"given":"Qian","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ran","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haojun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,9,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia Gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1471-2377-10-46","article-title":"A Systematic Review of Population Based Epidemiological Studies in Myasthenia Gravis","volume":"10","author":"Carr","year":"2010","journal-title":"BMC Neurol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-018-8751-9","article-title":"Myasthenia Gravis and Infectious Disease","volume":"265","author":"Gilhus","year":"2018","journal-title":"J Neurol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1177\/039463201302600201","article-title":"Vaccines and Autoimmunity","volume":"26","author":"De Martino","year":"2013","journal-title":"Int J Immunopathol Pharmacol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/mus.22077","article-title":"Safety of Influenza and H1N1 Vaccinations in Patients with Myasthenia Gravis, and Patient Compliance","volume":"43","author":"Auriel","year":"2011","journal-title":"Muscle Nerve"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27224","article-title":"The Influenza Vaccination in Autoimmune Neuromuscular Diseases: A Survey of Current Practices and Perceptions","volume":"63","author":"Roy","year":"2021","journal-title":"Muscle Nerve"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26689","article-title":"Factors Associated With Acute Exacerbations of Myasthenia Gravis","volume":"60","author":"Gummi","year":"2019","journal-title":"Muscle Nerve"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14153","article-title":"Serious Infections in Patients With Myasthenia Gravis: Population-Based Cohort Study","volume":"27","author":"Kassardjian","year":"2020","journal-title":"Eur J Neurol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1023\/a:1026683007277","article-title":"Myasthenia Gravis: Another Autoimmune Disease Associated With Hepatitis C Virus Infection","volume":"44","author":"Eddy","year":"1999","journal-title":"Dig Dis Sci"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2011.03.019","article-title":"HIV-Associated Myasthenia Gravis and Impacts of HAART: One Case Report and a Brief Review","volume":"113","author":"Hung","year":"2011","journal-title":"Clin Neurol Neurosurg"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jns.2010.02.016","article-title":"Neuromuscular Disorders Associated With Hepatitis B Vaccination","volume":"292","author":"St\u00fcbgen","year":"2010","journal-title":"J Neurol Sci"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2009.11.011","article-title":"Geoepidemiology of Myasthenia Gravis [Corrected]","volume":"9","author":"Meyer","year":"2010","journal-title":"Autoimmun Rev"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000003697","article-title":"Zika Virus Infection and Myasthenia Gravis: Report of 2 Cases","volume":"88","author":"Molko","year":"2017","journal-title":"Neurology"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.170993","article-title":"Molecular Mimicry of Human Endothelial Cell Antigen by Autoantibodies to Nonstructural Protein 1 of Dengue Virus","volume":"286","author":"Liu","year":"2011","journal-title":"J\u00a0Biol Chem"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.7326\/l20-0845","article-title":"Myasthenia Gravis Associated With SARS-CoV-2 Infection","volume":"173","author":"Restivo","year":"2020","journal-title":"Ann Intern Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2013.03.010","article-title":"Etiology of Myasthenia Gravis: Innate Immunity Signature in Pathological Thymus","volume":"12","author":"Cavalcante","year":"2013","journal-title":"Autoimmun Rev"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181d7d884","article-title":"Detection of Poliovirus-Infected Macrophages in Thymus of Patients With Myasthenia Gravis","volume":"74","author":"Cavalcante","year":"2010","journal-title":"Neurology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/s0140-6736(94)92657-3","article-title":"Human Foamy Virus Infection in Myasthenia Gravis","volume":"343","author":"Sa\u00efb","year":"1994","journal-title":"Lancet"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2018.03.036","article-title":"Detection of Human Parvovirus B19 Infection in the Thymus of Patients With Thymic Hyperplasia-Associated Myasthenia Gravis","volume":"25","author":"Gong","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e62","DOI":"10.1371\/journal.ppat.0020062","article-title":"The Thymus Is a Common Target Organ in Infectious Diseases","volume":"2","author":"Savino","year":"2006","journal-title":"PloS Pathog"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/ene.12703","article-title":"Myasthenia Gravis: Descriptive Analysis of Life-Threatening Events in a Recent Nationwide Registry","volume":"22","author":"Ramos-Fransi","year":"2015","journal-title":"Eur J Neurol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1080\/1040841x.2019.1614904","article-title":"The Role of Viral Infections in the Development of Autoimmune Diseases","volume":"45","author":"Hussein","year":"2019","journal-title":"Crit Rev Microbiol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2009.05.005","article-title":"Infections and Autoimmunity\u2013Friends or Foes","volume":"30","author":"Kivity","year":"2009","journal-title":"Trends Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.cell.2006.02.015","article-title":"Pathogen Recognition and Innate Immunity","volume":"124","author":"Akira","year":"2006","journal-title":"Cell"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.01.073","article-title":"Safety of Vaccine Adjuvants: Focus on Autoimmunity","volume":"33","author":"van der Laan","year":"2015","journal-title":"Vaccine"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1097\/wco.0000000000000318","article-title":"Vaccine-Associated Inflammatory Diseases of the Central Nervous System: From Signals to Causation","volume":"29","author":"Nguyen","year":"2016","journal-title":"Curr Opin Neurol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.734689","article-title":"HLA Does Not Impact on Short-Medium-Term Antibody Response to Preventive Anti-SARS-Cov-2 Vaccine","volume":"12","author":"Ragone","year":"2021","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/s0098-2997(98)00002-8","article-title":"Molecular Basis of Vaccination","volume":"19","author":"Del Giudice","year":"1998","journal-title":"Mol Aspects Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2039","article-title":"Immunological Mechanisms of Vaccination","volume":"12","author":"Pulendran","year":"2011","journal-title":"Nat Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2015.05.014","article-title":"On Vaccine\u2019s Adjuvants and Autoimmunity: Current Evidence and Future Perspectives","volume":"14","author":"Pellegrino","year":"2015","journal-title":"Autoimmun Rev"},{"key":"B31","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.phrs.2015.08.003","article-title":"Vaccines, Adjuvants and Autoimmunity","volume":"100","author":"Guimar\u00e3es","year":"2015","journal-title":"Pharmacol Res"},{"key":"B32","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.coi.2020.08.008","article-title":"New Horizons in Adjuvants for Vaccine Development","volume":"65","author":"Reed","year":"2020","journal-title":"Curr Opin Immunol"},{"key":"B33","first-page":"65","article-title":"Quantifying the Possible Cross-Reactivity Risk of an HPV16 Vaccine","volume":"8","author":"Kanduc","year":"2009","journal-title":"J Exp Ther Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.4161\/self.1.4.13315","article-title":"No Human Protein Is Exempt From Bacterial Motifs, Not Even One","volume":"1","author":"Trost","year":"2010","journal-title":"Self Nonself"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.2741\/s341","article-title":"Peptide Cross-Reactivity: The Original Sin of Vaccines","volume":"4","author":"Kanduc","year":"2012","journal-title":"Front Biosci (Schol Ed)"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2017.151","article-title":"Vaccine-Induced Autoimmunity: The Role of Molecular Mimicry and Immune Crossreaction","volume":"15","author":"Segal","year":"2018","journal-title":"Cell Mol Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1159\/000502889","article-title":"Human Papillomavirus Epitope Mimicry and Autoimmunity: The Molecular Truth of Peptide Sharing","volume":"86","author":"Kanduc","year":"2019","journal-title":"Pathobiology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jaut.2010.07.003","article-title":"\u2018ASIA\u2019 - Autoimmune\/Inflammatory Syndrome Induced by Adjuvants","volume":"36","author":"Shoenfeld","year":"2011","journal-title":"J Autoimmun"},{"key":"B39","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jaut.2015.02.005","article-title":"Revisiting Adverse Reactions to Vaccines: A Critical Appraisal of Autoimmune Syndrome Induced by Adjuvants (ASIA)","volume":"59","author":"Hawkes","year":"2015","journal-title":"J Autoimmun"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2010.00978.x","article-title":"Use of Defined TLR Ligands as Adjuvants Within Human Vaccines","volume":"239","author":"Duthie","year":"2011","journal-title":"Immunol Rev"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0b013e3181eaca65","article-title":"Toll-Like Receptor Agonists: Are They Good Adjuvants","volume":"16","author":"Gnjatic","year":"2010","journal-title":"Cancer J"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/836485","article-title":"The Effects of TLR Activation on T-Cell Development and Differentiation","volume":"2012","author":"Jin","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.immuni.2010.10.002","article-title":"Vaccine Adjuvants: Putting Innate Immunity to Work","volume":"33","author":"Coffman","year":"2010","journal-title":"Immunity"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1055\/s-0040-1716334","article-title":"Medical, Genomic, and Evolutionary Aspects of the Peptide Sharing Between Pathogens, Primates, and Humans","volume":"7","author":"Kanduc","year":"2020","journal-title":"Glob Med Genet"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13546","article-title":"Roles of Cytokines and T Cells in the Pathogenesis of Myasthenia Gravis","volume":"203","author":"Uzawa","year":"2020","journal-title":"Clin Exp Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.04.011","article-title":"T Follicular Helper Cell Biology: A Decade of Discovery and Diseases","volume":"50","author":"Crotty","year":"2019","journal-title":"Immunity"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1007\/s10753-012-9526-6","article-title":"Possible Involvement of Toll-Like Receptors in the Pathogenesis of Myasthenia Gravis","volume":"36","author":"Wang","year":"2013","journal-title":"Inflammation"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9440(10)62960-4","article-title":"Increased Toll-Like Receptor 4 Expression in Thymus of Myasthenic Patients With Thymitis and Thymic Involution","volume":"167","author":"Bernasconi","year":"2005","journal-title":"Am J Pathol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-016-8549-4","article-title":"Review on Toll-Like Receptor Activation in Myasthenia Gravis: Application to the Development of New Experimental Models","volume":"52","author":"Robinet","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1002\/ana.23791","article-title":"Implication of Double-Stranded RNA Signaling in the Etiology of Autoimmune Myasthenia Gravis","volume":"73","author":"Cufi","year":"2013","journal-title":"Ann Neurol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.jaut.2013.12.013","article-title":"Innate Immunity in Myasthenia Gravis Thymus: Pathogenic Effects of Toll-Like Receptor 4 Signaling on Autoimmunity","volume":"52","author":"Cordiglieri","year":"2014","journal-title":"J Autoimmun"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2015.12.007","article-title":"Increased Expression of Toll-Like Receptors 7 and 9 in Myasthenia Gravis Thymus Characterized by Active Epstein-Barr Virus Infection","volume":"221","author":"Cavalcante","year":"2016","journal-title":"Immunobiology"},{"key":"B53","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/nyas.13534","article-title":"Toll-Like Receptors 7 and 9 in Myasthenia Gravis Thymus: Amplifiers of Autoimmunity","volume":"1413","author":"Cavalcante","year":"2018","journal-title":"Ann N Y Acad Sci"},{"key":"B54","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.jaut.2013.12.016","article-title":"Central Role of Interferon-Beta in Thymic Events Leading to Myasthenia Gravis","volume":"52","author":"Cufi","year":"2014","journal-title":"J\u00a0Autoimmun"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.10.6757","article-title":"Reversible Blockade of Thymic Output: An Inherent Part of TLR Ligand-Mediated Immune Response","volume":"181","author":"D\u00e9moulins","year":"2008","journal-title":"J Immunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0803809","article-title":"Activation of Melanoma Differentiation-Associated Gene 5 Causes Rapid Involution of the Thymus","volume":"182","author":"Anz","year":"2009","journal-title":"J Immunol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/s12883-018-1233-y","article-title":"Myasthenia Gravis Following Human Papillomavirus Vaccination: A Case Report","volume":"18","author":"Chung","year":"2018","journal-title":"BMC Neurol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000008757","article-title":"New Onset of Myasthenia Gravis After Intravesical Bacillus Calmette-Guerin: A Case Report and Literature Review","volume":"96","author":"Takizawa","year":"2017","journal-title":"Med (Baltimore)"},{"key":"B59","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1002\/mus.26328","article-title":"New Onset of Seropositive Generalized Myasthenia Gravis Following Intravesical Bacille Calmette-Guerin Treatment for Bladder Cancer: A Case Study","volume":"59","author":"Davalos","year":"2019","journal-title":"Muscle Nerve"},{"key":"B60","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1002\/ana.25267","article-title":"Molecular and Clinical Relationship Between Live-Attenuated Japanese Encephalitis Vaccination and Childhood Onset Myasthenia Gravis","volume":"84","author":"He","year":"2018","journal-title":"Ann Neurol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(03)14802-7","article-title":"Vaccination and Autoimmune Disease: What Is the Evidence","volume":"362","author":"Wraith","year":"2003","journal-title":"Lancet"},{"key":"B62","doi-asserted-by":"publisher","first-page":"170","DOI":"10.12688\/f1000research.22600.2","article-title":"Causality Assessment of Adverse Events Following Immunization: The Problem of Multifactorial Pathology","volume":"9","author":"Bellavite","year":"2020","journal-title":"F1000Res"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.01.042","article-title":"Optimal Approaches to Data Collection and Analysis of Potential Immune Mediated Disorders in Clinical Trials of New Vaccines","volume":"31","author":"Tavares Da Silva","year":"2013","journal-title":"Vaccine"},{"key":"B64","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.phrs.2014.08.002","article-title":"Predicting Post-Vaccination Autoimmunity: Who Might be at Risk","volume":"92","author":"Soriano","year":"2015","journal-title":"Pharmacol Res"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1002\/mus.21440","article-title":"Safety of Influenza Vaccination in Patients With Myasthenia Gravis: A Population-Based Study","volume":"40","author":"Zinman","year":"2009","journal-title":"Muscle Nerve"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2013.01.012","article-title":"Effective Humoral Immunity Against Diphtheria and Tetanus in Patients With Systemic Lupus Erythematosus or Myasthenia Gravis","volume":"54","author":"Csuka","year":"2013","journal-title":"Mol Immunol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2018.01.007","article-title":"Acetylcholine Receptor Antibody Titers and Clinical Course After Influenza Vaccination in Patients With Myasthenia Gravis: A Double-Blind Randomized Controlled Trial (ProPATIent-Trial)","volume":"28","author":"Tackenberg","year":"2018","journal-title":"EBioMedicine"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3988\/jcn.2017.13.4.325","article-title":"The Impacts of Influenza Infection and Vaccination on Exacerbation of Myasthenia Gravis","volume":"13","author":"Seok","year":"2017","journal-title":"J Clin Neurol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.09.078","article-title":"A Prospective, Placebo Controlled Study on the Humoral Immune Response to and Safety of Tetanus Revaccination in Myasthenia Gravis","volume":"35","author":"Strijbos","year":"2017","journal-title":"Vaccine"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.01.007","article-title":"A Prospective, Double-Blind, Randomized, Placebo-Controlled Study on the Efficacy and Safety of Influenza Vaccination in Myasthenia Gravis","volume":"37","author":"Strijbos","year":"2019","journal-title":"Vaccine"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker102","article-title":"Vaccination of Children and Adolescents With Rheumatic Diseases","volume":"50","author":"Dell\u2019 Era","year":"2011","journal-title":"Rheumatol (Oxford)"},{"key":"B72","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/art.25033","article-title":"Humoral Responses After Influenza Vaccination Are Severely Reduced in Patients With Rheumatoid Arthritis Treated With Rituximab","volume":"62","author":"van Assen","year":"2010","journal-title":"Arthritis Rheum"},{"key":"B73","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/art.25034","article-title":"Immunization Responses in Rheumatoid Arthritis Patients Treated With Rituximab: Results From a Controlled Clinical Trial","volume":"62","author":"Bingham","year":"2010","journal-title":"Arthritis Rheum"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2011.10.015","article-title":"Vaccination of Patients With Auto-Immune Inflammatory Rheumatic Diseases Requires Careful Benefit-Risk Assessment","volume":"11","author":"Bijl","year":"2012","journal-title":"Autoimmun Rev"},{"key":"B75","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1093\/cid\/cit684","article-title":"2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin Infect Dis"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2017-000484","article-title":"Pneumococcal Vaccination in Autoimmune Rheumatic Diseases","volume":"3","author":"R\u00e1k\u00f3czi","year":"2017","journal-title":"RMD Open"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.07.039","article-title":"The Effect of Immunosuppressive Agents on Immunogenicity of Pneumococcal Vaccination: A Systematic Review and Meta-Analysis","volume":"36","author":"van Aalst","year":"2018","journal-title":"Vaccine"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1056\/nejm199111213252101","article-title":"The Protective Efficacy of Polyvalent Pneumococcal Polysaccharide Vaccine","volume":"325","author":"Shapiro","year":"1991","journal-title":"N Engl J Med"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2014.206","article-title":"Vaccination of Patients With Autoimmune Inflammatory Rheumatic Diseases","volume":"11","author":"Westra","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220647","article-title":"Immunogenicity and Safety of the BNT162b2 mRNA COVID-19 Vaccine in Adult Patients With Autoimmune Inflammatory Rheumatic Diseases and in the General Population: A Multicentre Study","author":"Furer","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B81","doi-asserted-by":"publisher","first-page":"R38","DOI":"10.1186\/ar2174","article-title":"Vaccination Response to Tetanus Toxoid and 23-Valent Pneumococcal Vaccines Following Administration of a Single Dose of Abatacept: A Randomized, Open-Label, Parallel Group Study in Healthy Subjects","volume":"9","author":"Tay","year":"2007","journal-title":"Arthritis Res Ther"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22246","article-title":"Effect of Methotrexate, Anti-Tumor Necrosis Factor \u03b1, and Rituximab on the Immune Response to Influenza and Pneumococcal Vaccines in Patients With Rheumatoid Arthritis: A Systematic Review and Meta-Analysis","volume":"66","author":"Hua","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kei193","article-title":"Influence of Methotrexate, TNF Blockers and Prednisolone on Antibody Responses to Pneumococcal Polysaccharide Vaccine in Patients With Rheumatoid Arthritis","volume":"45","author":"Kapetanovic","year":"2006","journal-title":"Rheumatol (Oxford)"},{"key":"B84","doi-asserted-by":"publisher","first-page":"R171","DOI":"10.1186\/ar4358","article-title":"Rituximab and Abatacept But Not Tocilizumab Impair Antibody Response to Pneumococcal Conjugate Vaccine in Patients With Rheumatoid Arthritis","volume":"15","author":"Crnkic Kapetanovic","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"B85","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.trsl.2015.08.008","article-title":"Autoimmune Disease and Vaccination: Impact on Infectious Disease Prevention and a Look at Future Applications","volume":"167","author":"McKinnon","year":"2016","journal-title":"Trans Res"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.08.011","article-title":"Immunosuppressive Drugs Impairs Antibody Response of the Polysaccharide and Conjugated Pneumococcal Vaccines in Patients With Crohn\u2019s Disease","volume":"33","author":"Kants\u00f8","year":"2015","journal-title":"Vaccine"},{"key":"B87","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41577-020-00479-7","article-title":"A Guide to Vaccinology: From Basic Principles to New Developments","volume":"21","author":"Pollard","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2020.08.355","article-title":"Mortality Rates and Causes of Death in Swedish Myasthenia Gravis Patients","volume":"30","author":"Westerberg","year":"2020","journal-title":"Neuromuscul Disord"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1086\/587063","article-title":"Vaccination in Patients With Chronic Rheumatic or Autoimmune Diseases","volume":"46","author":"Gl\u00fcck","year":"2008","journal-title":"Clin Infect Dis"},{"key":"B90","unstructured":"VACCINATIONS: Myasthenia Gravis Foundation of America2021"},{"key":"B91","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","article-title":"2019 Update of EULAR Recommendations for Vaccination in Adult Patients With Autoimmune Inflammatory Rheumatic Diseases","volume":"79","author":"Furer","year":"2020","journal-title":"Ann Rheumatic Dis"},{"key":"B92","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/mus.26382","article-title":"Health Maintenance for Adults With Neuromuscular Diseases on Immunosuppression","volume":"59","author":"Cartwright","year":"2019","journal-title":"Muscle Nerve"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2021-244146","article-title":"Temporal Association Between SARS-CoV-2 and New-Onset Myasthenia Gravis: Is it Causal or Coincidental","volume":"14","author":"Muralidhar Reddy","year":"2021","journal-title":"BMJ Case Rep"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2021-244102","article-title":"Transient Acetylcholine Receptor-Related Myasthenia Gravis, Post Multisystem Inflammatory Syndrome in Children (MIS-C) Temporally Associated With COVID-19 Infection","volume":"14","author":"Essajee","year":"2021","journal-title":"BMJ Case Rep"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxrep.2020.04.012","article-title":"Editorial: Nicotine and SARS-CoV-2: COVID-19 may be a Disease of the Nicotinic Cholinergic System","volume":"7","author":"Farsalinos","year":"2020","journal-title":"Toxicol Rep"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2020.100051","article-title":"Pathogenic Priming Likely Contributes to Serious and Critical Illness and Mortality in COVID-19 via Autoimmunity","volume":"3","author":"Lyons-Weiler","year":"2020","journal-title":"J Transl Autoimmun"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.617089","article-title":"Reaction of Human Monoclonal Antibodies to SARS-CoV-2 Proteins With Tissue Antigens: Implications for Autoimmune Diseases","volume":"11","author":"Vojdani","year":"2020","journal-title":"Front Immunol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102791","article-title":"Molecular Mimicry Between SARS-CoV-2 and Human Proteins","volume":"20","author":"Adiguzel","year":"2021","journal-title":"Autoimmun Rev"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14813","article-title":"MuSK-Positive Myasthenia May Not Only Be Triggered by SARS-CoV-2","author":"Finsterer","year":"2021","journal-title":"Eur J Neurol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jaci.2020.05.008","article-title":"Elevated Levels of IL-6 and CRP Predict the Need for Mechanical Ventilation in COVID-19","volume":"146","author":"Herold","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpha.2020.03.001","article-title":"Molecular Immune Pathogenesis and Diagnosis of COVID-19","volume":"10","author":"Li","year":"2020","journal-title":"J Pharm Anal"},{"key":"B102","volume-title":"COVID-19 Vaccine Tracker and Landscape","year":"2021"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-020-09152-6","article-title":"Molecular Mimicry Between SARS-CoV-2 Spike Glycoprotein and Mammalian Proteomes: Implications for the Vaccine","volume":"68","author":"Kanduc","year":"2020","journal-title":"Immunol Res"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220059","article-title":"SARS-CoV-2 Vaccine Hesitancy Among Patients With Rheumatic and Musculoskeletal Diseases: A Message for Rheumatologists","volume":"80","author":"Priori","year":"","journal-title":"Ann Rheum Dis"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2008.200","article-title":"Incorporation of Pseudouridine Into mRNA Yields Superior Nonimmunogenic Vector With Increased Translational Capacity and Biological Stability","volume":"16","author":"Karik\u00f3","year":"2008","journal-title":"Mol Ther"},{"key":"B106","doi-asserted-by":"publisher","first-page":"e142","DOI":"10.1093\/nar\/gkr695","article-title":"Generating the Optimal mRNA for Therapy: HPLC Purification Eliminates Immune Activation and Improves Translation of Nucleoside-Modified, Protein-Encoding mRNA","volume":"39","author":"Karik\u00f3","year":"2011","journal-title":"Nucleic Acids Res"},{"key":"B107","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3390\/vaccines9050435","article-title":"Immune-Mediated Disease Flares or New-Onset Disease in 27 Subjects Following mRNA\/DNA SARS-CoV-2 Vaccination","volume":"9","author":"Watad","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.15581","article-title":"A Case of COVID-19 Vaccine Causing a Myasthenia Gravis Crisis","volume":"13","author":"Tagliaferri","year":"2021","journal-title":"Cureus"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220231","article-title":"Safety of\u00a0the\u00a0First\u00a0Dose of\u00a0mRNA SARS-CoV-2\u00a0Vaccines in\u00a0Patients With Rheumatic and Musculoskeletal Diseases","author":"Connolly","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220503","article-title":"Disease Activity and Humoral Response in Patients With Inflammatory Rheumatic Diseases After Two Doses of the Pfizer mRNA Vaccine Against SARS-CoV-2","author":"Braun-Moscovici","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220656","article-title":"High Antibody Response to Two-Dose SARS-CoV-2 Messenger RNA Vaccination in Patients With Rheumatic and Musculoskeletal Diseases","author":"Ruddy","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220289","article-title":"Antibody Response to a Single Dose of SARS-CoV-2 mRNA Vaccine in Patients With Rheumatic and Musculoskeletal Diseases","author":"Boyarsky","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2021.102649","article-title":"A Recommended Paradigm for Vaccination of Rheumatic Disease Patients With the SARS-CoV-2 Vaccine","volume":"121","author":"Moutsopoulos","year":"2021","journal-title":"J Autoimmun"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219808","article-title":"SARS-CoV-2 Antibody Response After COVID-19 in Patients With Rheumatic Disease","author":"D\u2019Silva","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220148","article-title":"Correspondence on \u2018SARS-CoV-2 Antibody Response After COVID-19 in Patients With Rheumatic Disease\u2019","author":"SK","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2814-7","article-title":"COVID-19 Vaccine BNT162b1 Elicits Human Antibody and T(H)1 T Cell Responses","volume":"586","author":"Sahin","year":"2020","journal-title":"Nature"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.5603\/PJNNS.a2021.0054","article-title":"COVID-19 Pandemic Year in a Sample of Polish Myasthenia Gravis Patients: An Observational Study","author":"Rzepi\u0144ski","year":"2021","journal-title":"Neurol Neurochir Pol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-10149-2","article-title":"Management of Patients With Neuromuscular Disorders at the Time of the SARS-CoV-2 Pandemic","volume":"268","author":"Costamagna","year":"2021","journal-title":"J\u00a0Neurol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(20)30413-0","article-title":"COVID-19-Associated Risks and Effects in Myasthenia Gravis (CARE-Mg)","volume":"19","author":"Muppidi","year":"2020","journal-title":"Lancet Neurol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000011669","article-title":"Impact of Coronavirus Disease 2019 in a French Cohort of Myasthenia Gravis","volume":"96","author":"Sol\u00e9","year":"2021","journal-title":"Neurology"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2020.117230","article-title":"Immunosuppression in Chronic Autoimmune Neurological Disorders During the COVID-19 Pandemic","volume":"420","author":"Kovvuru","year":"2021","journal-title":"J Neurol Sci"},{"key":"B122","unstructured":"CDC Announces Authorization of Additional COVID-19 Vaccine Dose for People With Compromised Immune Systems, Including Patients With Myasthenia Gravis (MG) Taking Immunosuppressive Treatment(s) 2021"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1002\/art.41877","article-title":"American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 2","volume":"73","author":"Curtis","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2021-002933","article-title":"Comparison of Medium-Term Adverse Reactions Induced by the First and Second Dose of mRNA BNT162b2 (Comirnaty, Pfizer-BioNTech) Vaccine: A Post-Marketing Italian Study Conducted Between 1 January and 28 February 2021","author":"Ossato","year":"2021","journal-title":"Eur J Hosp Pharm"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.664179","article-title":"Challenges and Issues of Anti-SARS-CoV-2 Vaccines","volume":"8","author":"Blumental","year":"2021","journal-title":"Front Med (Lausanne)"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.733418\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T06:09:02Z","timestamp":1631858942000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.733418\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,17]]},"references-count":125,"alternative-id":["10.3389\/fimmu.2021.733418"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.733418","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,17]]},"article-number":"733418"}}